VHL-CNS-Hb | vs. | Control | VHL-pNET | vs. | Control | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
(N = 220) | (N = 1,100) | (N = 20) | (N = 100) | |||||||||
Demographic characteristics | ||||||||||||
Female, N (%) | 136 | (61.8%) | 678 | (61.6%) | 12 | (60.0%) | 60 | (60.0%) | ||||
Age at index date (years), mean ± SD | 49.0 | ± 11.3 | 49.0 | ± 11.2 | 47.1 | ± 14.1 | 47.1 | ± 13.8 | ||||
Geographic region, N (%) | ||||||||||||
Northeast | 22 | (10.0%) | 107 | (9.7%) | < 5 | - | 8 | (8.0%) | ||||
Midwest | 51 | (23.2%) | 284 | (25.8%) | 5 | (25.0%) | 19 | (19.0%) | ||||
South | 108 | (49.1%) | 479 | (43.5%) | 10 | (50.0%) | 51 | (51.0%) | ||||
West | 38 | (17.3%) | 220 | (20.0%) | < 5 | - | 22 | (22.0%) | ||||
Unknown | < 5 | - | 10 | (0.9%) | < 5 | - | < 5 | - | ||||
Health insurance type, N (%) | ||||||||||||
EPO | 19 | (8.6%) | 108 | (9.8%) | < 5 | - | 8 | (8.0%) | ||||
PPO | 17 | (7.7%) | 42 | (3.8%) | < 5 | - | 5 | (5.0%) | ||||
POS | 123 | (55.9%) | 723 | (65.7%) | 12 | (60.0%) | 74 | (74.0%) | ||||
HMO | 44 | (20.0%) | 184 | (16.7%) | < 5 | - | 10 | (10.0%) | ||||
Other1 | 19 | (8.6%) | 42 | (3.8%) | < 5 | - | < 5 | - | ||||
Disease characteristics | ||||||||||||
Year of index date, N (%) | ||||||||||||
2018 − 2012 | 85 | (38.6%) | 425 | (38.6%) | 8 | (40.0%) | 40 | (40.0%) | ||||
2013–2016 | 75 | (34.1%) | 375 | (34.1%) | < 5 | - | 10 | (10.0%) | ||||
2017–2020 | 60 | (27.3%) | 300 | (27.3%) | 10 | (50.0%) | 50 | (50.0%) | ||||
Comorbidities | ||||||||||||
CCI, mean ± SD | 2.0 | ± 2.6 | 0.4 | ± 1.0 | *** | 2.8 | ± 3.6 | 0.3 | ± 0.8 | *** | ||
Comorbidities, N (%) | ||||||||||||
Hypertension | 100 | (45.5%) | 327 | (29.7%) | *** | 11 | (55.0%) | 28 | (28.0%) | * | ||
Depression/anxiety | 73 | (33.2%) | 181 | (16.5%) | *** | 9 | (45.0%) | 19 | (19.0%) | * | ||
Chronic pulmonary disease | 54 | (24.5%) | 103 | (9.4%) | *** | < 5 | - | 12 | (12.0%) | |||
Diabetes | 34 | (15.5%) | 108 | (9.8%) | * | 7 | (35.0%) | 5 | (5.0%) | ** | ||
Osteoporosis/fractures | 30 | (13.6%) | 59 | (5.4%) | *** | < 5 | - | 6 | (6.0%) | |||
Liver disease | 37 | (16.8%) | 33 | (3.0%) | *** | < 5 | - | < 5 | - | * | ||
Cerebrovascular disease | 51 | (23.2%) | 27 | (2.5%) | *** | < 5 | - | < 5 | - | |||
Congestive heart failure | 8 | (3.6%) | 23 | (2.1%) | < 5 | - | < 5 | - | ||||
Peripheral vascular disease | 19 | (8.6%) | 22 | (2.0%) | *** | < 5 | - | < 5 | - | |||
Renal disease | 24 | (10.9%) | 20 | (1.8%) | *** | < 5 | - | < 5 | - | |||
Cancer | 50 | (22.7%) | 43 | (3.9%) | *** | 7 | (35.0%) | < 5 | - | ** | ||
Annual HRU during baseline, mean ± SD | ||||||||||||
Inpatient visits | 0.7 | ± 1.7 | 0.1 | ± 0.6 | *** | 1.5 | ± 3.7 | 0.1 | ± 0.5 | |||
Inpatient days | 2.9 | ± 7.4 | 0.8 | ± 7.5 | *** | 4.0 | ± 5.9 | 0.3 | ± 1.0 | * | ||
ED visits | 1.8 | ± 4.7 | 0.6 | ± 1.8 | *** | 0.5 | ± 0.8 | 1.0 | ± 3.7 | |||
Outpatient visits | 15.2 | ± 10.6 | 7.7 | ± 8.8 | *** | 20.1 | ± 11.3 | 7.1 | ± 8.3 | *** | ||
Other visits2 | 1.8 | ± 2.9 | 0.8 | ± 2.2 | *** | 2.1 | ± 3.2 | 0.5 | ± 1.3 | * | ||
Annual healthcare costs during baseline, mean ± SD | ||||||||||||
Total costs | $44,688 | ± $92,113 | $9,102 | ± $40,331 | *** | $51,768 | ± $76,003 | $5,911 | ± $13,839 | ** | ||
Medical costs | $38,869 | ± $87,536 | $7,371 | ± $39,206 | *** | $46,657 | ± $75,751 | $3,309 | ± $6,529 | ** | ||
Inpatient costs | $21,270 | ± $75,640 | $3,435 | ± $34,478 | *** | $9,443 | ± $13,806 | $916 | ± $4,409 | ** | ||
ED costs | $3,600 | ± $12,781 | $635 | ± $2,579 | *** | $1,244 | ± $2,191 | $443 | ± $1,458 | |||
Outpatient costs | $13,519 | ± $36,804 | $3,122 | ± $11,500 | *** | $35,221 | ± $76,519 | $1,917 | ± $3,364 | * | ||
Other costs2 | $480 | ± $2,513 | $178 | ± $1,685 | * | $749 | ± $1,514 | $33 | ± $106 | * | ||
Pharmacy costs | $5,819 | ± $22,709 | $1,731 | ± $7,090 | ** | $5,112 | ± $9,488 | $2,602 | ± $11,823 |